Share

Novo Nordisk A/S (NOV.XETRA) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+60.6%

Includes 4.49% annual net dividend contribution

1. Investment Thesis — Base Case

Novo's central tension is arithmetic rather than narrative: volumes are compounding while realised price collapses, and the market has priced only the second half of that sentence. The February 2026 guidance cut and the 18% gap to DKK 302 [2] anchored expectations so firmly that two subsequent upward revisions [3][4] produced declines. Base case: 2027 marks the earnings trough, oral semaglutide restores volume-led growth, cost discipline under a new CEO recovers several margin points, and the multiple drifts from distressed toward defensive-pharma normal — without ever regaining growth-stock status, because the 2031 patent horizon caps terminal value.

Adjusted TTM EPS near USD 3.2-3.4 after stripping the USD 4.2bn 340B reversal implies roughly 13x.
Drift toward 14-15x on modestly recovering supports roughly EUR 48-50 by late 2031.
USD 192bn market capitalisation against USD 11.75bn TTM : a 6.1% yield funding the payout.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (EUR)
Observed price	2021-09-14	42.4
Observed price	2021-09-22	43.1
Observed price	2021-10-04	41.6
Observed price	2021-10-12	42.2
Observed price	2021-10-28	46.3
Observed price	2021-11-01	47.3
Observed price	2021-11-17	50.7
Observed price	2021-12-03	47.1
Observed price	2021-12-11	50.8
Observed price	2021-12-19	49.0
Observed price	2022-01-08	44.9
Observed price	2022-01-24	40.8
Observed price	2022-02-01	45.1
Observed price	2022-02-09	45.9
Observed price	2022-02-21	44.4
Observed price	2022-03-01	46.8
Observed price	2022-03-21	49.9
Observed price	2022-03-25	48.4
Observed price	2022-04-14	55.3
Observed price	2022-04-18	54.1
Observed price	2022-04-22	51.0
Observed price	2022-05-16	49.4
Observed price	2022-06-01	51.8
Observed price	2022-06-09	53.1
Observed price	2022-06-17	50.2
Observed price	2022-06-29	52.9
Observed price	2022-07-15	56.5
Observed price	2022-07-31	57.0
Observed price	2022-08-08	50.3
Observed price	2022-08-16	51.7
Observed price	2022-08-24	54.6
Observed price	2022-09-09	53.6
Observed price	2022-09-25	50.0
Observed price	2022-10-03	51.7
Observed price	2022-10-11	53.7
Observed price	2022-10-27	53.8
Observed price	2022-11-08	57.2
Observed price	2022-11-20	55.4
Observed price	2022-12-10	60.8
Observed price	2022-12-18	62.3
Observed price	2023-01-03	63.9
Observed price	2023-01-11	61.9
Observed price	2023-01-19	65.0
Observed price	2023-02-04	63.4
Observed price	2023-02-20	66.7
Observed price	2023-03-04	68.0
Observed price	2023-03-16	66.1
Observed price	2023-03-20	67.0
Observed price	2023-04-09	73.8
Observed price	2023-04-13	75.5
Observed price	2023-04-17	77.5
Observed price	2023-05-07	75.4
Observed price	2023-05-19	79.0
Observed price	2023-05-31	75.0
Observed price	2023-06-12	73.3
Observed price	2023-07-02	72.9
Observed price	2023-07-14	71.0
Observed price	2023-07-22	73.9
Observed price	2023-07-26	71.2
Observed price	2023-08-15	83.8
Observed price	2023-08-23	87.4
Observed price	2023-09-12	91.5
Observed price	2023-09-24	86.7
Observed price	2023-10-02	85.4
Observed price	2023-10-18	95.6
Observed price	2023-10-26	90.6
Observed price	2023-11-07	94.5
Observed price	2023-11-15	89.9
Observed price	2023-11-23	95.5
Observed price	2023-12-09	89.1
Observed price	2023-12-21	93.8
Observed price	2024-01-02	94.3
Observed price	2024-01-18	98.5
Observed price	2024-01-26	97.7
Observed price	2024-02-15	114
Observed price	2024-02-27	113
Observed price	2024-03-10	122
Observed price	2024-03-14	121
Observed price	2024-04-03	116
Observed price	2024-04-19	116
Observed price	2024-04-27	119
Observed price	2024-05-05	116
Observed price	2024-05-21	124
Observed price	2024-05-29	123
Observed price	2024-06-10	133
Observed price	2024-06-26	135
Observed price	2024-07-04	131
Observed price	2024-07-12	130
Observed price	2024-07-28	118
Observed price	2024-08-05	114
Observed price	2024-08-17	124
Observed price	2024-09-02	124
Observed price	2024-09-10	117
Observed price	2024-09-22	113
Observed price	2024-10-04	104
Observed price	2024-10-16	108
Observed price	2024-11-05	99.9
Observed price	2024-11-13	102
Observed price	2024-11-17	96.7
Observed price	2024-12-11	106
Observed price	2024-12-23	83.3
Observed price	2025-01-04	84.4
Observed price	2025-01-16	79.1
Observed price	2025-01-20	77.2
Observed price	2025-02-09	83.1
Observed price	2025-02-13	76.8
Observed price	2025-02-25	85.8
Observed price	2025-03-09	75.8
Observed price	2025-03-29	63.8
Observed price	2025-04-02	62.4
Observed price	2025-04-18	52.3
Observed price	2025-04-26	55.0
Observed price	2025-05-04	59.9
Observed price	2025-05-28	60.8
Observed price	2025-06-09	65.4
Observed price	2025-06-13	69.5
Observed price	2025-06-25	58.4
Observed price	2025-07-23	59.4
Observed price	2025-07-27	53.6
Observed price	2025-08-04	42.3
Observed price	2025-08-20	46.4
Observed price	2025-09-01	48.9
Observed price	2025-09-09	45.4
Observed price	2025-09-21	51.1
Observed price	2025-09-29	47.3
Observed price	2025-10-11	50.4
Observed price	2025-10-31	42.6
Observed price	2025-11-12	42.9
Observed price	2025-11-24	38.8
Observed price	2025-11-28	42.4
Observed price	2025-12-06	40.7
Observed price	2025-12-22	40.7
Observed price	2026-01-11	50.7
Observed price	2026-01-23	53.1
Observed price	2026-02-04	43.3
Observed price	2026-02-16	41.7
Observed price	2026-02-28	31.8
Observed price	2026-03-08	34.0
Observed price	2026-03-24	31.7
Observed price	2026-03-28	30.6
Observed price	2026-04-17	34.5
Observed price	2026-04-21	34.0
Observed price	2026-05-11	39.9
Observed price	2026-05-27	38.7
Observed price	2026-06-04	38.1
Observed price	2026-06-08	36.3
Observed price	2026-06-28	42.1
Observed price	2026-07-02	44.2
Observed price	2026-07-14	42.7
Observed price	2026-07-30	44.1
Observed price	2026-08-15	39.3
Observed price	2026-08-23	40.1
Observed price	2026-09-08	39.0
Observed price	2026-09-12	37.1
Observed price	2026-09-24	33.7
Observed price	2026-09-25	33.9
Published advisor forecast	2026-09-18	37.6
Published advisor forecast	2026-12-18	36.4
Published advisor forecast	2027-03-18	38.3
Published advisor forecast	2027-06-18	39.4
Published advisor forecast	2027-09-18	40.2
Published advisor forecast	2027-12-18	41.8
Published advisor forecast	2028-03-18	43.1
Published advisor forecast	2028-06-18	43.9
Published advisor forecast	2028-09-18	45.2
Published advisor forecast	2028-12-18	46.1
Published advisor forecast	2029-03-18	47.5
Published advisor forecast	2029-06-18	48.5
Published advisor forecast	2029-09-18	49.5
Published advisor forecast	2029-12-18	50.4
Published advisor forecast	2030-03-18	50.9
Published advisor forecast	2030-06-18	51.5
Published advisor forecast	2030-09-18	51.5
Published advisor forecast	2030-12-18	50.4
Published advisor forecast	2031-03-18	49.9
Published advisor forecast	2031-06-18	48.9
Published advisor forecast	2031-09-18	48.4

2. Scenarios & Signals

Bull case

The bull case activates when approval and access arrive together. A broad CagriSema label in late 2026 [14], followed by expanded federal obesity coverage, converts the MFN price concession into a volume annuity rather than a permanent haircut. Volume growth then laps the reset price base, capex normalises from 19.5% of revenue, and free cash flow accelerates faster than earnings — inviting both an upsized buyback and multiple expansion toward mid-teens. Total return compounds well above the base path.

Bear case

The bear case needs only one thing: proof that Novo cannot innovate past semaglutide. A CagriSema CRL in late 2026, followed by February 2027 guidance confirming a second consecutive decline, would reframe the company as a single-molecule business approaching a 2031 cliff. Lilly's orforglipron and retatrutide then accelerate share capture, the 4.2% dividend starts looking like a payout ratio problem against 58% cash conversion, and the multiple compresses toward 9x. Capital destruction, not just underperformance.

Current crowd narrative

The settled belief: Lilly won the obesity war and Novo is a melting ice cube with a dividend. Consensus treats MFN price cuts as permanent, CagriSema as dead on arrival, and the 12-13x multiple as deserved. The anchoring bias is the February guidance cut and the 18% gap to DKK 302 [2] — two subsequent upward revisions [3][4] were dismissed as noise.

Alpha-gap assessment

Modestly underpriced, with an important caveat the bulls ignore. The decisive overlooked evidence is behavioural: management raised guidance twice in 2026 [3][4] and the shares fell each time, which is capitulation behaviour, not information processing. But the bear case is closer to right than value screens suggest — the supplied trailing PE of 10.60 is flattered by the USD 4.2bn 340B rebate reversal [1]; adjusted, it is nearer 13x on an base consensus expects to fall again in 2027 [6]. The gap is real but narrow.

Convergence catalyst

February 2027's full-year report is the hinge: it either confirms 2026 as the earnings trough with a renewed buyback and restructuring target, or validates a second down year. The first observable sign of repricing is an upgrade following Morgan Stanley's September downgrade [21].

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.4
Expected volatility regime: high_erratic
Convergence-cycle position: capitulation

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
ORAL Wegovy Breaks THE Capacity Chokepoi	The pill is the strongest evidence in the file: over three million US prescriptions since launch and roughly 207,000 weekly scripts by week fifteen, outpacing tirzepatide [9][10]. Oral delivery bypasses the fill-finish bottleneck that throttled injectable supply, converting semaglutide into a distribution-led primary-care franchise. Volume strength forced two upward guidance revisions during 2026 [3][4], and it persists while composition-of-matter protection holds.	Not available	+19.0%
A Dividend Floor THE Foundation WILL DEF	FY2025 dividend of DKK 11.70 plus the DKK 3.75 interim gives a TTM yield of 4.21%, corroborated by the supplied outflow-normalised figure, alongside a DKK 15bn repurchase that has retired more than 32 million B shares [17][18]. Novo Holdings' A-share control makes payout continuity a governance commitment, not a discretionary choice [19][20]. That floor caps de-rating and pays investors to wait through the price reset.	Not available	+13.0%
Trading Price FOR Reimbursed Patient YEA	Under the November 2025 Most Favoured Nations agreement, Novo surrendered realised price for statutory access across Medicare Part D, Medicaid and self-pay at USD 149-299 monthly [5][8]. That crushed 2026 revenue but converts a cash-pay niche into chronic reimbursed therapy. On an 81% gross-margin molecule, incremental volume against a reset price base restores operating leverage from 2028 onward; the access, once legislated, is sticky.	Not available	+11.0%
NEW CEO Sharper Knife ON Costs	Doustdar's rebrand and corporate restructuring agenda, discussed publicly ahead of the analyst meeting [22], follows a visible pruning of low-conviction assets including the monlunabant termination after a USD 1.1bn transaction [7]. With operating margin down from 44.2% to 41.4% and R&D at DKK 51.9bn, the cost base carries genuine slack. Disciplined reinvestment should restore several margin points by 2028-2029.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Price IS Losing THE Volume Trade	Q1 2026 adjusted sales fell 11% at constant exchange rates on lower realised prices, partly offset by volume [5]. MFN concessions plus loss of exclusivity in International Operations markets mean each new patient arrives at a structurally lower net price. This is a permanent reset of the revenue-per-script anchor, not a cycle; consensus already expects 2027 EPS of DKK 21.98 below 2026's DKK 23.03 [6], a second consecutive decline.	Not available	-16.0%
Lilly's TWO Front Advance	Orforglipron was FDA-approved as Foundayo on 1 April 2026 [11], with JP Morgan projecting USD 6bn by 2027 [12], while retatrutide delivered 29% mean weight loss in TRIUMPH-4 [16] against CagriSema's 22.7% [9]. Lilly's 2026 revenue guidance of USD 80-83bn [13] funds a marketing arms race Novo cannot outspend. Share loss compresses both Novo's volume trajectory and the terminal multiple investors will pay.	Not available	-15.0%
THE 2031 Cliff Enters THE Discount Windo	Semaglutide generics already launched in India and Canadian generics are approved [8]; US and EU composition-of-matter protection lapses around 2031-2032 on my working assumption, unverified in the evidence. Equity markets discount a pharma patent cliff roughly two years ahead, meaning the back half of this horizon carries a structural multiple cap regardless of interim execution. That mechanically limits terminal re-rating even in a good operational outcome.	Not available	-13.0%
THE Krone Quote Imports A Dollar Problem	Management flagged that DKK-reported adjusted sales growth runs three percentage points below CER and operating profit growth five points below, primarily on USD/DKK depreciation [1][23]. With EUR/USD at 1.15 and DKK pegged inside the ERM II band, the XETRA EUR line inherits this drag without hedging benefit. Persistent dollar softness under a resilient-but-tightening Fed keeps translation a recurring subtraction from reported earnings.	Not available	-8.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Government Coverage Floodgate Opens	The MFN framework already routes semaglutide into Medicare Part D and Medicaid [5]. If CMS moves during 2027-2028 to broad, explicit obesity coverage across federal programmes, reimbursed patient-years step-change higher precisely when oral supply is unconstrained. Novo's primary-care distribution would capture disproportionate script share, turning the 2026 price concession into an annuity and forcing consensus to model volume growth above price erosion. Below 50% because fiscal pressure, budget-scoring rules and a contested policy environment make the timing and breadth genuinely uncertain.	33.0%	+31.0%
Cagrisema Lands A Broad Label	Novo filed with a decision expected late 2026, though no PDUFA date was publicly confirmed as of July 2026 [14][15]. If approval arrives in Q4 2026 or H1 2027 with a broad obesity label and a credible cardiometabolic positioning despite failing to match Zepbound, the market regains a pipeline asset it currently values near zero. A DKK 15-20bn peak-sales franchise would lift 2029 EPS by a tenth and, more importantly, break the narrative that Novo cannot innovate past semaglutide. Below 50% because the REDEFINE-1 efficacy gap invites label and pricing constraints.	40.0%	+26.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Patent WALL Breached Early	An adverse US patent ruling, an expedited generic settlement, or IRA-negotiated pricing on semaglutide biting from 2027-2028 would pull the cliff forward by years. Because roughly four-fifths of group revenue rests on one molecule, an earlier erosion date would force the market to discount a terminal-decline business rather than a maturing franchise, halving the justified multiple. Probability stays below 50% because composition-of-matter protection to 2031-2032 is well litigated and Novo retains formulation and device layers.	22.0%	-37.0%
Complete Response Letter PLUS A Second DOWN YEAR	If the FDA issues a CRL or a heavily restricted CagriSema label in late 2026, and February 2027 guidance confirms a second consecutive decline consistent with consensus EPS of DKK 21.98 [6], the value case collapses into a value trap. Two down years with a compromised pipeline invites the multiple to compress toward 9-10x even with the dividend intact. Below 50% because the filing is complete and REDEFINE-1 showed 22.7% weight loss [9], clinically approvable if unexciting.	38.0%	-27.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_6f780607-cd2a-5455-b7f4-184664cae5bb__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (EUR)	Scenario rationale
1	December 18, 2026	-3.0%	36.44	The CagriSema decision window and the analyst meeting both land this quarter. A narrow label or conservative 2027 framing keeps sellers in control, while 5% Treasury yields and year-end tax-loss selling add pressure. Dividend support limits the damage.
2	March 18, 2027	+5.0%	38.27	February's full-year report defines 2026 as the trough and renews the DKK 15bn buyback. Restructuring targets plus evidence that oral Wegovy volumes are offsetting MFN price cuts trigger the first upgrade cycle since September's downgrade.
3	June 18, 2027	+3.0%	39.41	Q1 2027 delivers the first clean comparison once the USD 4.2bn 340B reversal laps, exposing genuine underlying volume growth in obesity care. Modest multiple expansion follows as investors finally separate accounting noise from commercial momentum.
4	September 18, 2027	+2.0%	40.20	Summer consolidation. Lilly's orforglipron ramp toward JP Morgan's USD 6bn estimate caps enthusiasm, while European and Chinese growth holds. With the Fed's terminal midpoint near 4.1%, rate relief does not arrive to help the multiple.
5	December 18, 2027	+4.0%	41.81	Preliminary 2028 framing points back to constant-currency growth for the first time since 2025. Next-generation amycretin and combination readouts restore pipeline optionality that the market currently values at approximately zero, lifting the terminal assumption.
6	March 18, 2028	+3.0%	43.06	Full-year 2027 results confirm the trough has passed. Capex normalising from roughly 19% of revenue lifts free cash flow conversion above the depressed 58% of 2025, funding a larger repurchase alongside the maintained dividend.
7	June 18, 2028	+2.0%	43.92	Volume-led growth continues while generic erosion in India, Brazil and Canada offsets part of it. The multiple grinds toward the mid-teens as slower global growth pushes allocators back into defensive cash-generative pharmaceutical exposure.
8	September 18, 2028	+3.0%	45.24	Broader Medicare and Medicaid obesity coverage expands reimbursed patient-years materially. Novo's oral franchise captures disproportionate primary-care prescribing share, translating statutory access into revenue growth rather than further discount concessions and lifting margin recovery expectations.
9	December 18, 2028	+2.0%	46.15	Year-end positioning favours quality defensives as the tightening cycle finally plateaus. Novo's restructuring delivers visible operating margin recovery toward the high thirties, validating the cost thesis while competitive intensity prevents any enthusiastic re-rating.
10	March 18, 2029	+3.0%	47.53	Full-year 2028 results show revenue and operating profit both growing, ending the three-year reset narrative. Buyback capacity expands as free cash flow conversion recovers, and per-share economics improve faster than headline earnings.
11	June 18, 2029	+2.0%	48.48	Steady grind higher on volume compounding. CagriSema or next-generation launch economics become quantifiable rather than speculative, though Lilly's retatrutide rollout keeps a firm ceiling on how much share Novo can realistically reclaim.
12	September 18, 2029	+2.0%	49.45	Mid-cycle stability. The franchise now resembles a mature, cash-generative cardiometabolic business rather than a growth story, with valuation settling near fourteen times earnings and a still-attractive dividend anchoring total return.
13	December 18, 2029	+2.0%	50.44	Capital returns dominate the story as capacity investment completes and depreciation stabilises. Management guides to a higher payout and expanded repurchase, supporting the share price even as underlying revenue growth settles at single digits.
14	March 18, 2030	+1.0%	50.95	Momentum fades as analysts begin building explicit 2031-2032 semaglutide loss-of-exclusivity scenarios into terminal models. Good current results no longer translate into multiple expansion; the discounting window on the patent cliff is opening.
15	June 18, 2030	+1.0%	51.46	Flat drift. Strong operating execution meets a market increasingly focused on what replaces semaglutide revenue after 2032. Pipeline depth becomes the sole determinant of valuation, and the evidence remains incomplete.
16	September 18, 2030	+0.0%	51.46	Stalemate quarter. Dividend yield and buyback fully offset the accumulating patent-cliff discount. Investors hold for income rather than appreciation, and trading volumes on the XETRA line thin as conviction on both sides weakens.
17	December 18, 2030	-2.0%	50.43	The cliff enters the twelve-month window. Sell-side models formally step down 2032-2033 revenue for US semaglutide generics, compressing the terminal multiple regardless of current-year performance. Income buyers absorb only part of the selling.
18	March 18, 2031	-1.0%	49.92	Full-year 2030 results are solid but the guidance commentary on post-exclusivity strategy dominates the reaction. Any acquisition to fill the revenue gap would raise leverage from an already elevated debt-to-equity base.
19	June 18, 2031	-2.0%	48.92	Generic filers position ahead of US expiry and International Operations erosion deepens. Earnings remain healthy while the market prices the decline, a familiar pharmaceutical pattern where the multiple falls before the numbers do.
20	September 18, 2031	-1.0%	48.43	Horizon closes with the equity valued on post-cliff earnings power rather than current results. Cumulative price appreciation near 29% plus reinvested dividends leaves a respectable but unspectacular total return versus alternatives.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]NOVO NORDISK A S - Form 6-K - FY2026sec.gov
[2]Novo Nordisk shares tumble 18% after 2026 sales dip warning - Pharmaceutical Technologypharmaceutical-technology.com
[3]NOVO NORDISK A S - Form 6-K - FY2026sec.gov
[4]Novo Nordisk shares slide after guidance disappoints investorscnbc.com
[5]Q1 2026 adjusted Obesity care sales increased by 22% at ...sec.gov
[6]Novo Nordisk stock dips as DKK 15 billion buyback advancesad-hoc-news.de
[7]Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring - Insight, China's Pharmaceutical Industryflcube.com
[8]Financial report for the period 1 January 2026 to 31 March 2026 6 May 2026ml-eu.globenewswire.com
[9]Novo Nordisk Q1 2026 slides: Wegovy pill drives outlook raise despite sales decline By Investing.cominvesting.com
[10]Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?finance.yahoo.com
[11]New Weight-Loss Pill Orforglipron Could Arrive in the UK by 2026privatemedicalclinic.com
[12]Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead | FirstWord Pharmafirstwordpharma.com
[13]ELI LILLY & Co - Form 8-K - FY2026sec.gov
[14]Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial misscnbc.com
[15]CagriSema FDA Review: Novo Nordisk NDA Timeline Explained | Life Science Daily Newslifesciencedaily.news
[16]eli lilly company q4 earnings 082658839finance.yahoo.com
[17]Dividend pay for Novo Nordisk investorsnovonordisk.com
[18]Novo Nordisk Dividend 2026 & forecast 2027 2028 2029 | ex-daystocksguide.com
[19]Novo Nordisk Stock Forecast | 2026 Sales Guidance Cut | Capital.comcapital.com
[20]Helge Lunden.wikipedia.org
[21]__symbol__ Stock Quote Price and Forecast | CNNcnn.com
[22]NVO: Novo Nordisk A/S - Stock Price, Quote and News - CNBCcnbc.com
[23]NOVO NORDISK A S - Form 6-K - FY2025sec.gov

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Michael Burry — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.